Lifecore inks biomaterial deal:
This article was originally published in Clinica
Lifecore Biomedical has entered into exclusive licence and development agreements with the Cleveland Clinic, in Ohio, to develop and commercialise hyaluronan-based products and related applications. It has licensed a patented hyaluronan-based cross-linking technology that can be used for products in aesthetics, orthopaedics, ophthalmology and other medical fields. The biomaterial is formed through a chemical reaction, catalysed by a naturally occurring molecule, which provides a spectrum of formulations that are stable, well-tolerated by the body, and able to mimic the function of a wide variety of tissues, while providing for tissue repair and reinforcement, said the Chaska, Minnesota firm. Lifecore believes the technology platform will allow it to expand in its existing markets and enter new markets.
You may also be interested in...
With Brexit less than a month old, Germany’s medtech industry has renewed its push for an MRA between the EU and UK in medtech regulation.
Days after a senior Chinese government official offered free COVID-19 vaccines to the Philippines government, the country’s medicines regulator said the donated jabs would need an emergency approval before they can be used on the public.
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.